Destiny Pharma plc reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was GBP 2.66 million compared to GBP 3.19 million a year ago. Basic loss per share from continuing operations was GBP 0.031 compared to GBP 0.048 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.25 GBX | -2.99% | -23.53% | -76.79% |
Apr. 25 | Norcros sells Johnson Tiles UK; Trifast trading well | AN |
Apr. 25 | Transcript : Destiny Pharma plc, 2023 Earnings Call, Apr 25, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-76.79% | 19.29M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- DEST Stock
- News Destiny Pharma plc
- Destiny Pharma plc Reports Earnings Results for the Half Year Ended June 30, 2023